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Abstract: Measurement of sub-clinical atopic dermatitis (AD) is important for determining 
how long therapies should be continued after clinical clearance of visible AD lesions. An 
important biomarker of sub-clinical AD is epidermal hypertrophy, the structural measures of 
which often make optical coherence tomography (OCT) challenging due to the lack of a 
clearly delineated dermal-epidermal junction in AD patients. Alternatively, angiographic 
OCT measurements of vascular depth and morphology may represent a robust biomarker for 
quantifying the severity of clinical and sub-clinical AD. To investigate this, angiographic data 
sets were acquired from 32 patients with a range of AD severities. Deeper vascular layers 
within skin were found to correlate with increasing clinical severity. Furthermore, for AD 
patients exhibiting no clinical symptoms, the superficial plexus depth was found to be 
significantly deeper than healthy patients at both the elbow (p = 0.04) and knee (p<0.001), 
suggesting that sub-clinical changes in severity can be detected. Furthermore, the morphology 
of vessels appeared altered in patients with severe AD, with significantly different vessel 
diameter, length, density and fractal dimension. These metrics provide valuable insight into 
the sub-clinical severity of the condition, allowing the effects of treatments to be monitored 
past the point of clinical remission. 
© 2018 Optical Society of America under the terms of the OSA Open Access Publishing Agreement 
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1. Introduction 
Atopic dermatitis (AD  synonym atopic eczema) is a chronic, inflammatory disorder of the 
skin which has a profound effect on quality of life. The prevalence of the condition within the 
US is estimated to be approximately 10.7% for child AD [1] (Global  7.3% [2]) and 10.2% 
for adult AD [3], and is generally increasing within both the developed and developing world 
[2,4]. Symptoms include dry, itchy, erythematous skin, which exhibit abnormalities such as 
increased trans-epidermal water loss (TEWL) [5]. These symptoms arise due to complex 
interactions between many different genes and environmental factors, which lead to a 
defective epidermal barrier and Th 2 driven inflammation [6]. Clinical assessment of the 
extent and severity of AD is typically performed using external grading systems such as the 
severity scoring of AD [7] (SCORAD) or the eczema area and severity index [8] (EASI) 
which look for specific signs and coverage of the condition. These externally visible signs 
include erythema, edema, papulation, excoriation, lichenification and oozing [8]. There is 
however substantial evidence that unaffected, lesion-free skin sites of AD patients can remain 
abnormal, even following remission of the condition [9]. Such subclinical abnormalities 
include significant differences in TEWL, pH and capacitance between healthy and unaffected 
skin [10,11] as well as structural abnormalities such as epidermal thickening [9,12]. Indeed it 
appears clear that externally healthy looking skin of previously diagnosed AD patients is 
likely to contain hidden abnormalities beneath the skin surface [12]. Identification of these 
subclinical factors could facilitate improved treatments which aim to monitor and suppress 
progression of the disorder past the point of clinical remission [9]. 
Optical Coherence Tomography (OCT) is an established non-invasive medical-imaging 
technique which utilizes near-infrared light to capture a reflectance profile of the sub-surface 
layers within skin. Previous studies have utilized the high axial resolution (~5-10たm) of OCT 
to delineate the dermal-epidermal junction (DEJ) within skin, allowing for automated 
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measurements of epidermal thickness [1315]. In the context of AD, measurements of 
epidermal atrophy (thinning) following corticosteroid treatment have been well documented 
using both OCT [1618] and other non-invasive modalities [18,19]. In contrast, epidermal 
thickening, associated with skin inflammation [12], is more challenging to accurately quantify 
using simple structural OCT, owing to a reduction in contrast between the epidermal and 
dermal layers of the skin as the epidermis thickens and the dermal papillae extend upwards 
(Sec. 3.2). To avoid subjective and time-consuming manual measurements of epidermal 
thickness, an alternative method of quantifying the degree of thickening could be to measure 
the depth of vascular layers of the skin. Firstly, the superficial plexus which lies horizontally 
in the upper papillary dermis could be considered a lower boundary for the true DEJ location. 
Secondly, the tips of the capillary loops which extend vertically into each of the dermal 
papillae represent the thinnest points of the epidermis and could be considered an upper 
boundary for the DEJ location (Fig. 1). The depths of these vessel layers are likely to be 
influenced by inflammation, as a thickening epidermis will push the superficial plexus deeper 
into the tissue. 
 
Fig. 1. The structure of skin affected by epidermal thickening (Sebaceous glands and sweat 
ducts omitted for clarity). Vertical arteries and capillaries rise from the deep plexus and form a 
horizontal network termed the superficial plexus (SP). From this, capillary loops consisting of 
both rising arterioles and falling venules form hairpin like structures in the dermal papillae. A) 
An en-face angiographic svOCT image captured at a depth corresponding to the tips of the 
capillary loops, visible as small dots in the en-face perspective. B) An en-face angiographic 
svOCT image captured at a depth corresponding to the SP. Large interconnected vessels are 
visible. The depth of these layers may provide a direct measure of the tissue inflammation. 
Recently developed processing methods have enabled the extraction of three-dimensional 
angiographic data from oversampled structural OCT data sets [20,21], which has enabled 
further study of numerous dermatological conditions [22]. One such method, termed speckle-
variance OCT (svOCT) identifies the presence of fluid flow by considering the temporal 
evolution of intensity (speckle) within each pixel of a volume. Pixels in a solid region of 
tissue exhibit intensities which can be characterized by a Gaussian distribution, due to static 
coherent speckle and random acquisition noise. Comparatively, pixels in a fluid region of 
tissue will exhibit intensities in a Rayleigh distribution, as a combination of both acquisition 
noise and moving speckle [23]. This gives rise to contrast between solid and fluid regions of 
the skin. 
The aims of this study are two-fold: firstly, we aim to develop and validate angiographic 
OCT for automated measurements of epidermal thickness within skin affected with a range of 
AD severities. Secondly, we aim to investigate whether subclinical morphological differences 
within the microcirculation of AD patients correlate with the severity of the condition. 
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2. Materials and methods 
2.1 Participants 
A total of 32 volunteers were recruited for this study. Both male and female volunteers aged 
18-60 with Fitzpatrick skin type I-III (Mexameter melanin reading of <350) were considered 
on a first-come first served basis. Exclusion criteria included pregnancy, folliculitis, acne, 
suntan, hyperpigmentation, multiple nevi, tattoos, blemishes or dense body hair in the test 
areas. Cosmetic products were also restricted prior to the study initiation. Of the 32 
participants; 5 were healthy, having no prior history of any chronic skin condition (Including 
AD). The remaining 27 participants had currently active AD (As defined by the UK working 
party diagnostic criteria) at a range of severities, as well as having no history of any other 
chronic skin conditions. Informed consent was obtained from each participant prior to 
imaging. The National Research Ethics Service (NRES) Committee East MidlandsDerby, 
formally known as Trent Multicentre Research Ethics Committee (MREC), approved the 
study, under the project reference 04/MREC/70. 
2.2 Imaging protocol 
All imaging for this study was performed using a multi-beam OCT system (Vivosight, 
Michelson Diagnostics Ltd, Orpington, Kent, UK) running at 20 kHz line acquisition rate. 
This system utilizes a swept-source 1305nm Axsun laser with a bandwidth of 147nm, 
allowing visualization of structures to a depth of ~1mm in skin. Four imaging sites which 
commonly exhibit AD symptoms were chosen for the study, these being the left and right 
cubital fossa (crook of the elbow) as well as the left and right popliteal fossa (crook of the 
knee). 
 
Fig. 2. The OCT imaging set-up used for this study. A mechanical clamp (A) was used to fix 
the Vivosight imaging probe (B) into place above the region of interest. The vertical stage of 
the clamp (C) was then lowered such that the plastic cap (D) gently touched the surface of the 
skin (E). This plastic cap reduced any lateral (sliding) motion between the probe and the skin. 
Data was then transferred to the optical processing unit of the OCT system through a cable (F). 
Prior to imaging, each participant was asked to wait 20 minutes in the study room with the 
skin of the test sites exposed, this process aimed to acclimatize each of the test sites such that 
any homeostatic variance was minimized. Following this, each skin site of the participant was 
assessed independently by two different graders to establish severity scores based on dryness, 
erythema, edema/papulation, excoriation and lichenification, assigning a number between 0 
and 3 for each. A local EASI score for each specific skin site was defined as the sum of each 
of these severity scores, averaged between the two assessors. A global (full-body) EASI score 
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was calculated for each participant through a similar scoring and area coverage assessment at 
the head/neck, upper limbs, trunk and lower limb regions following previously described 
weighting and methodology [8]. The handheld probe of the OCT system was then positioned 
for imaging using a mechanical clamp, such that any movement artifacts originating from the 
operator were eliminated. A plastic cap bridged the gap between the OCT probe and the skin, 
which was deemed necessary to reduce any lateral sliding of the skin surface during imaging. 
The OCT imaging set-up is illustrated in Fig. 2. Given that the imaging protocol involves 
physical contact with the skin surface, one might expect some degree of vasoconstriction 
through the white dermographism response which is common within AD affected skin [24]. 
White dermographism within AD is known to have a relatively long onset (23 ± 1.4s) with 
comparatively short duration (6 ± 1s) [25]. Thus, in order to reduce the influence of this effect 
on the resulting vascular data, a delay of approximately 30 seconds was added following the 
fixation of the imaging probe. 
Imaging was then performed, with four-dimensional (x-y-z-time) structural OCT volumes 
being collected from each skin site in turn. All scans captured a volume of 4x4x2mm with 10 
repeat B-scans being collected at each y-location such that a measure of variance could be 
calculated as per the svOCT methodology. The first 12 AD patient data sets were acquired 
with a 10たm A-scan spacing in the x-direction (fast scan) and a 20たm A-scan spacing in the 
y-direction (slow scan), with these scans taking approximately 50 seconds to acquire and save 
(40-frames/s). While the angiographic quality of these scans was sufficiently high for vessel 
depth measurement, the decision was made to increase the A-scan spacing in the y-direction 
to 10たm such that uniform spacing between scans was achieved, further increasing scan 
quality while doubling the required acquisition time. The remaining 20 data sets were 
acquired with this 10たm A-scan spacing (In both x and y) with each scan taking 
approximately 100 seconds to acquire and save. The increased resolution of these scans had 
no notable effect on the measurement of vascular layers (Sec. 2.4) but greatly enhanced the 
vascular morphology measurements (Sec. 2.3), thus quantification of vascular morphology 
was restricted only to data sets which were acquired with the higher resolution. The raw data 
was processed offline in MATLAB (R2014b  MathWorks) into an angiographic format 
following a previously described methodology [21,26]. Motion artefacts were suppressed by 
registering each of the repeat B-scans to the first B-scan captured at each location, using a 
sub-pixel accurate cross-correlation based algorithm to an accuracy of 100th of a pixel [27]. 
A combined wavelet-FFT filter was then utilized to effectively suppress any remaining 
motion artefacts with minimal degradation to the underlying vascular information [21,26]. 
This filter works by considering that a vertical line artefact has a high-frequency component 
in the horizontal (x) direction and a low frequency component in the vertical (y) direction. 
Vertical information within the volume is first extracted through wavelet decomposition, 
which high-pass filters the rows and low-pass filters the columns. The resulting image is then 
Fourier transformed, and frequency components along the x-axis are suppressed using a 
damping function. The image is then inverse Fourier transformed and repackaged together 
with its corresponding detail, horizontal and diagonal wavelet bands. Further details of this 
filter can be found in a previous publication [26]. 
2.3 Automatic quantification of vascular morphology 
For both automatic quantification of microvessel morphology and plexus depth (Sec. 2.4) it 
was necessary to binarize the angiographic data such that vascular skeletons could be 
generated. Figure 3 shows the steps that were taken to skeletonize the data. 
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Fig. 3. Steps taken to skeletonize and quantify vascular parameters from angiographic data 
sets. A) En-face mean intensity projection captured from the popliteal fossa site of a healthy 
participant. White box shows the FOV used for B-G. B) Median filtering step. C) Multiscale 
Hessian filtering. D) Result of masking B with the vesselness data in C. E) Resulting 
skeleton (Green) overlaid on the masked data. F) Measured vessel diameter at each point along 
the vessel. 
Firstly, an angiographic image was generated by performing mean-intensity-projections 
(MIP) over the depth range of interest (Fig. 3(A)), this image was median filtered to remove 
noise (Fig. 3(B)). The image was then processed with a Hessian filtering algorithm [28], 
which quantifies the vesselness of a pixel through consideration of the eigenvalues of the 
local Hessian matrix. To minimize artificial vessel dilation following Hessian filtering, a 
multi-scale approach was used. Compared to a single-scale approach, which uses gaussian 
kernels with a single value of j in order to build the Hessian matrix, the multi-scale approach 
uses a range of j values in order to consider a range of vessel scales. Here values of 1:10 
were used for j, corresponding to vessel scales of 10-100たm, with the strongest detection 
(maximum value) of each pixel across all vessel scales being recorded (Fig. 3(C)). The values 
of j were selected empirically and offered reliable performance over the vessel scales 
observed here, with minimal vessel dilation being qualitatively visible. The filtered image 
was then used to compose a mask for the original data, preserving only areas of signal which 
were likely to be vascular derived (Fig. 3(D)). These filtering steps were deemed necessary 
due to the large magnitude of svOCT background noise, some of which is derived from 
movement of the participant during imaging. Following these steps, the image was binarized 
using an automatically determined threshold (Otsus method [29]), with this binary image 
then being used to generate a vessel skeleton (Fig. 3(E)). 
Four quantitative parameters were extracted using both the binarized data together with 
the vascular skeleton. Average vessel diameter (たm) was defined as double the average 
distance from the skeleton to the closest zero in the binarized image. Average vessel length 
(たm) was defined as the average length of skeleton segments between branching points in the 
skeleton, measured using a geodesic distance transform [30]. Vessel density (Vessels/mm
2) 
was calculated by dividing the total number of vessel segments in the image by the size of the 
area (16mm2). Lastly, the fractal dimension of the skeleton network was calculated using the 
box-counting method [31], which outputs a value between 0 and 3, with higher values 
indicating a more irregular and tortuous network. 
2.4 Automatic quantification of vascular depth 
As discussed in Sec. 1, the capillary loop depth (CLD) and superficial plexus depth (SPD) 
within skin could potentially be used as a robust measure of acanthosis (epidermal 
hypertrophy). In our previous work, measurements of CLD and SPD were acquired 
qualitatively through visual observation of an en-face flythrough of the corresponding 
angiographic data [32]. Here, the skeletonization procedure outlined in Sec. 2.3 is used to 
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automate this step. Firstly, a pseudo-3D skeleton was generated over the entire visible depth 
range (0-1mm) by applying the skeletonization methodology to each z-depth in turn. With 
OCT angiography, forward scattering of photons by the red blood cells result in a shadowing 
artefact beneath detected vasculature [33]. This effect was utilized to improve the 
skeletonization further, as signal derived from the vasculature was present over a range of 
depths within the tissue, while noise-derived signal was inconsistent with respect to depth. A 
simple median filter of 3-pixel window size in the z-direction was used to remove skeleton 
points which were inconsistent with depth. The total number of independent skeleton 
segments was then calculated for each z-depth in the volume. In this context, an independent 
skeleton section was defined as a section of skeleton that was disconnected from other 
sections of the skeleton. As there is no vasculature present in the upper sections of the 
epidermis, there were no independent skeleton segments detected for superficial depths. Once 
the tips of capillary loops start entering the field-of-view (typically around 40-100たm in 
depth) the number of independent skeleton segments increased rapidly until reaching a local 
maximum. This maximum value represents the point at which the maximum number of 
unconnected capillary loops are visible, and is thus defined as the CLD. Typically at the CLD 
depth, between 200 and 500 independent skeleton sections were observed (corresponding to 
13-31 capillaries per mm2), this is in agreement with known measurements of the capillary 
density within skin, which typically range from 10 to 70 capillaries per mm2 of skin [34]. 
Following the CLD, one might expect the number of independent skeleton segments to 
plateau as subsequent depths are simply following each loop along its axis. Instead, the value 
gradually reduces, suggesting that the vessel network almost immediately begins to 
interconnect. This is potentially a direct result of the ascending and descending limbs of each 
capillary loop spreading slightly apart with depth, as OCT lacks the resolution to clearly 
discriminate between each limb. The result is a dilation of the visible loops, with neighboring 
loops potentially merging together though not physically connected. At sufficient depth, the 
gradient of the curve of skeleton segment number vs depth reaches 0, suggesting that the 
network is fully connected; this point is defined as the SPD. The SPD depth was more 
challenging to automatically quantify, owing to an increase in noise and a lack of OCT signal 
at deeper depths in the tissue. To improve reliability of this detection, the curve was smoothed 
with a moving averaging filter which spanned ~20たm and each detection was manually 
checked for reliability. In future, SPD detection can potentially be improved through use of an 
alternate metric which would peak at the SPD depth, such as the total vessel signal or length, 
however this was not explored in the context of this study. Typically, past the SPD depth, the 
number of independent skeleton sections fluctuate slightly due to inconsistencies in the 
shadowing artefact of the vasculature, until reaching the noise floor, at which point a final 
reduction in value is observed. The noise floor in this context is the point at which the entire 
en-face angiogram shows detected speckle-variance due to random noise in the corresponding 
structural images, resulting in an extremely interconnected skeleton and a low number of 
independent skeleton segments. Figure 4 illustrates this process for both healthy and AD skin, 
with healthy skin typically exhibiting a thin peak at superficial depths and AD skin typically 
exhibiting a much wider peak at comparatively deeper depths in the tissue. 
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Fig. 4. Automatic measurement of CLD and SPD through consideration of the number of 
independent (non-connected) skeleton segments as a function of tissue depth. The top row 
shows the results for a healthy participant at the left cubital fossa: the local maximum (CLD) is 
located at 42.9たm beneath the skin surface, while the following local minima (SPD) is located 
at 132.6たm beneath the surface. The bottom row shows the results for a participant with AD 
(Local EASI = 5.25) at the left cubital fossa: the local maximum (CLD) is located at 89.4たm 
beneath the skin surface, while the following local minima (SPD) is located at 304.2たm 
beneath the surface. 
2.5 Statistics 
Statistical analysis was carried out using MATLAB (R2014b  Mathworks). A one-way 
ANOVA followed by the Tukey-Kramer honest significance difference (HSD) test was used 
to test for significant differences between four different data sets (Sec. 3.1). In all cases, 
comparisons were described as significant if the probability of the null hypothesis was <0.05. 
All stated and graphed measurements are of the form mean ± standard deviation. 
3. Results 
3.1 Scan cohorts 
A total of 128 OCT data sets were acquired from the 32 participants, corresponding to 64 
scans at the cubital and popliteal fossa sites respectively. To aid in analysis, these scans were 
separated into four different data sets based on the presence of localized AD and their local 
EASI score. The healthy data set (n = 20) consisted of skin sites of participants with no prior 
history of AD. The unaffected data set (n = 35) consisted of the skin sites of AD participants 
with a local EASI score of 0, thus showing no visible external symptoms of AD. The mild 
AD data set (n = 40) consisted of the skin sites with a local EASI greater than 0 and less than 
5. Lastly the severe AD data set (n = 33) consisted of the skin sites with a local EASI greater 
than 5. The average global EASI score (full body) was 1.84 ± 0.92 for the unaffected data set, 
4.29 ± 4.69 for the mild data set and 7.57 ± 6.62 for the severe data set. It is important to note 
that in this context, a skin site being allocated to the severe/mild AD data sets simply meant 
that the localized AD appeared severe/mild and did not necessarily imply that the global 
severity would be graded as severe/mild. There was however a strong correlation to this 
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effect, as evidenced by the comparatively higher average global EASI scores for the mild and 
severe AD data sets. 
3.2 Automatic structural measurements of epidermal thickness 
To enable comparison with the vessel derived metrics, average epidermal thickness was 
automatically quantified for each of the data sets using an algorithm which has been 
previously validated in healthy skin [15]. Briefly, this automatic algorithm first detects the 
air-skin (stratum corneum) boundary through application of a Sobel edge detection filter 
which was optimized for detecting any sharp changes in image intensity (dark to bright) in the 
depth-direction. Superficial detected edges which exceeded a size threshold of 15-pixels were 
identified and interpolated across such that the entire stratum-corneum was detected. The 
thresholding of smaller detected edges reduced the sensitivity of this technique to noise and 
other artefacts, such as superficial hairs. The second step of the automatic algorithm aimed to 
detect the DEJ itself, which is characterized by a transition from a hyporeflective band to a 
more hyperreflective band, where the grainy keratinocytes of the spinosum meet the basement 
membrane of the papillary dermis. This is detected as a local-minima within each A-scan 
[35]. Minima which are sufficiently connected are interpolated between to form the complete 
DEJ detection. The average distance between the detected stratum-corneum and DEJ was 
used as a measure of the average epidermal thickness. 
To demonstrate this process, the structural OCT images seen in Fig. 5 have been averaged 
over 50 consecutive frames to reduce speckle-noise and improve clarity of the DEJ. The 
stratum corneum and DEJ in each image were segmented both manually by eye and 
automatically using the algorithm discussed above. Despite the averaging, the automated 
algorithm failed to accurately capture the complex geometry of the DEJ at the involved site, 
severely underestimating the true epidermal thickness. Failure in this case was determined 
through visual observation of each volume to check that the automatic segmentation was 
reasonable. This is problematic, as manual assessment of epidermal thickness is a time 
consuming and subjective task, particularly across volume regions of tissue. Across all data 
sets, detection of the DEJ using the automatic algorithm failed in 41 cases, with a high 
tendency towards failure at higher local EASI scores (Healthy = 1 failure, Mild AD = 11 
failures, Severe AD = 29 failures). The primary reason for failure was a distinct lack of 
contrast at the DEJ for many of the AD skin sites. Comparatively, automatic assessment of 
the CLD and SPD failed in 13 cases (Healthy = 1 failure, Unaffected AD = 2 failures, Mild 
AD = 5 failures, Severe AD = 5 failures) with motion corrupted data being the primary reason 
for failure. Angiographic post-processing at the bedside would enable repeat measurements to 
be made in cases where motion artefacts have corrupted the data, potentially reducing the 
failure rates of the angiographic method. For the structural method, we believe the loss of 
contrast at the DEJ is related to the presence of localized acanthosis; which involves the 
elongation of the rete-pegs/dermal papillae into the thickening epidermis, a condition 
previously documented in AD affected skin [36]. The result is a highly oscillatory DEJ which 
rises and falls around each individual rete-peg, these sharp undulations result in the lack of a 
clearly defined border between the epidermis and dermis. Furthermore, it remains challenging 
to consistently define epidermal thickness under these conditions as measurements fluctuate 
between thin sections of epidermis at the tips of the dermal papillae and at comparatively 
thick sections of epidermis along the deepest points along each rete-peg. 
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Fig. 5. Averaged (n = 50  acquired at the same location) OCT images of the popliteal-fossa 
highlighting the reduction of DEJ contrast as epidermal thickness increases. A) OCT image 
captured from a healthy subject (Local EASI = 0), showing clear delineation of the epidermis 
and dermis. B) OCT image captured from an uninvolved site on an eczema patient, showing 
slightly extended rete-pegs and an undulating DEJ. C) OCT image captured from an involved 
site on a different eczema patient, showing what appears to be inflammatory acanthosis (Long 
thin epidermal papillae/rete-pegs). D-F) Manually segmented skin layers, for these an observer 
simply traced the DEJ by eye, which is laborious and potentially subjective. G-I) 
Automatically segmented skin layers using the algorithm described above. For D-I, red lines 
are the skin surface / stratum corneum layer. Green coloration represents the epidermis, 
Yellow-lines are the DEJ and blue coloration represents the dermis. 
3.3 The effect of local severity on vascular depth 
Figure 6 shows a selection of 3D angiographic data sets from each data set at each unique 
skin site. Each image shows the depth resolved vasculature over a depth range of 40-275たm 
beneath the skin surface. 
 
Fig. 6. A selection of 3D angiographic OCT images projected over a depth range of 40-275たm 
beneath the skin surface. A-D) Scans from each data set captured from the cubital fossa 
(Elbow) skin site. E-H) Scans from each data set captured from the popliteal fossa (Knee) skin 
site. All images are 4x4mm. 
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Fig. 7. Top) Charts showing differences in the CLD, SPD and epidermal-dermal junction depth 
at both the cubital fossa and popliteal fossa skin sites for a range of AD severities. Columns: 
Mean depth. Bars: Standard deviation. Significance was calculated at each skin site 
independently using a one-way ANOVA followed by the Tukey-Kramer honest significance 
difference (HSD) test. Significance matrix colors correspond to the measured p-value (p>0.05 - 
Red, 0.05>p>0.005 - Orange, 0.005>p>0.0005 - Yellow, 0.0005>p - Green). Quoted data set 
sizes reflect angiography measurements only, as automatic epidermal-dermal junction 
assessment failed in a greater number of cases (With a bias towards failing in severe AD 
cases). Cohort sizes for the epidermal-dermal junction values were as follows: (From left to 
right): n = 9, 12, 14, 7, 9, 18, 13, 5. Bottom) Scatter plots showing the ungrouped SPD as a 
function of local EASI score, with a negative correlation visible at both sites. 1st degree 
polynomial fit was generated using all data points (Including healthy data). 
For the healthy data sets seen in Fig. 6, a highly connected plexus was visible over this 
depth range, suggesting that the epidermis remains relatively thin. In contrast, in cases of 
severe localized AD, numerous dots (capillary loops) could be seen with very few connecting 
vessels joining them together. As expected, this suggests that a thickened epidermis is 
present, as the superficial plexus has been pushed deeper into the tissue (>275たm). Cases of 
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unaffected or mild localized AD appear to bridge this gap with the connecting vascular plexus 
becoming less visible as the epidermis thickens. 
Figure 7 summarizes the results of automatic quantification of the CLD, SPD and 
epidermal-dermal junction depth across the entire data set. Measurements of the epidermal 
thickness (Blue columns) were included for comparative purposes. As expected due to 
localized inflammation, the thickness of the epidermis increases as the severity of localized 
AD increases. However, particularly for mild or severe cases of localized AD, the reported 
value of mean epidermal thickness is likely to be underestimated. This is a result of the 
automatic epidermal-dermal junction segmentation algorithm having an increased tendency to 
fail at thicker skin sites compared to areas with a thinner epidermis as discussed in Sec. 3.2 as 
evidenced by the comparatively smaller cohort sizes used for the mild/severe AD epidermal 
thickness measurements. This may explain the lack of any significance differences between 
the epidermal thickness of unaffected, mild and severe localized AD at the popliteal fossa 
skin site, as any thicknesses above approximately 100たm are unlikely to be measured 
accurately. 
Both the CLD (purple columns) and SPD (red columns) follow a similar trend to that of 
epidermal thickness, with an increase in depth as the severity of the localized AD increases 
(Fig. 7). For the case of the CLD, the differences are relatively small, with no significant 
differences found between the healthy and unaffected data sets at either skin site. Significant 
differences in CLD depth were however found between the healthy data set and the 
mild/severe data sets at both skin sites, suggesting that a significantly deepened CLD may be 
an indicator that the condition is clinically active with moderate localized severity. The SPD 
displayed comparatively greater differences between each data set. Of particular interest, 
significant differences in SPD were found between the healthy and unaffected data sets at 
both the elbow (p = 0.04) and the knee (p<0.001), suggesting that this metric could be used to 
as a means of differentiating between the two. This could prove useful when aiming to 
monitor the efficacy of a treatment for AD, past the point of clinical remission. Furthermore, 
for both skin sites, significant differences in SPD were recordable between the healthy and 
mild/severe data sets as well as between the severe and unaffected/mild data sets. This 
suggests that the metric may remain robust and be able to differentiate between more severe 
cases of the condition. 
Of potentially greater interest, SPD depth did discriminate between healthy (do not suffer 
from AD) skin and skin at the site of a healed flare (i.e. unaffected), whereas EASI did not 
(both skin types are assessed as EASI = zero). Similarly, no OCT-derived parameter, 
structural or angiographic, provided a strong discrimination between skin scored as 
unaffected and skin scored as mildly inflamed, even though the EASI scores are different. 
This could indicate that what is clinically scored as healed skin retains some physically 
detectable traits which are characteristic of mildly inflamed skin. In general, all three metrics 
followed a negative correlation as the local AD severity increased, suggesting that vascular 
measurements of CLD and SPD may have potential as robust measures of skin inflammation 
alongside epidermal thickness. Such measurement of the vascular layers may prove useful for 
monitoring the delicate balance between epidermal atrophy and acanthosis in response to 
topical corticosteroid application [17,19,37], particularly in areas of extreme thickening. 
Furthermore, since the inflammatory skin of AD can be characterized by altered angiogenesis 
[38,39], the depth and shape of the vasculature may hold additional information regarding the 
state of inflammation that is not provided by simple measures of epidermal thickness. Future 
research may focus on monitoring baseline variations of these parameters within the same 
patient over a period of time, a case where biological variability is far less likely to influence 
the data. 
The scatter plots shown at the bottom of Fig. 7 show how the ungrouped SPD 
measurements vary as a function of the local EASI score. While there is a negative correlation 
visible between the SPD depth and local EASI score at both the elbow (R = −0.53) and knee 
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(R = −0.37), the variation in the recorded measurements is high. This makes it unlikely that 
accurate estimates of the local EASI score could be inversely attained from measurements of 
the SPD depth. In a sense this is not concerning, as 100% correlation would imply that the 
SPD biomarker, which is technically difficult and expensive to measure, offers no additional 
information over EASI score, which is cheap and easy to assess by eye. Given that much of 
this variability can also likely be attributed to biological variations in the skin between 
different volunteers, one potential avenue of future work will be assessing how much 
variation remains when considering intra-patient measurements over a period of time. 
Furthermore, local EASI is a composite metric, combining multiple skin features (redness, 
excoriation, oedema and lichenification) in order to quantify the severity of the condition. The 
current study population was deemed insufficient for stratification on the individual signs, but 
it may be that SPD correlates more robustly with a particular sign. This idea is to be assessed 
in the future. 
3.4 The effect of severity on vascular morphology in the superficial vascular plexus 
One key output of the angiographic OCT processing technique is the availability of depth-
resolved en-face visualizations of the vascular network. The skin of patients with AD can be 
characterized by an abnormal erythematous vascular pattern visible from the surface of the 
skin [40]. Furthermore it is known that such patients exhibit abnormal vasoconstrictive 
responses to stimuli, including mechanical pressure (white dermographism [25]) and 
temperature [24]. Previously, differences in the microcirculatory flow of AD patients 
following treatment with a pimecrolimus cream have been quantified using laser doppler 
flowmetry [41]. Furthermore svOCT has been utilized to demonstrate the relevance of 
morphological vascular changes within inflammatory skin conditions including psoriasis and 
scleroderma [22]. Combined angiographic OCT and photoacoustic imaging has previously 
detected abnormal morphology and even potential micro aneurisms within skin affected by 
AD [42]. Thus, it is highly likely that the morphology of the vessels themselves will present 
some information regarding the severity of the AD. 
Previously we have shown that measurable morphological differences between healthy 
and AD scans are attainable using svOCT depth projections over a wide depth range (30-
300たm) [32], however it is unclear if the differences were related to true morphological 
differences or simply a result of the AD vessels being much deeper in the skin. To investigate 
this, the SPD data from Sec. 3.3 was utilized to acquire depth projections only over the depth 
range of the SPD ( ± 30たm). For example, if the SPD was recorded at a depth of 200たm, a 
projection image for quantification would be generated over the range 170-230たm, 
normalizing the depth considered to that of the SPD. This projection image was then 
skeletonized and quantified following the methodology outlined in Sec 2.3. 
Figure 8 shows a selection of the depth projected angiographic images which were used 
for quantification, while Fig. 9 shows the results of the quantification. Due to the sensitivity 
of these measurements to noise, and as discussed in Sec. 2.2, only scans which were acquired 
using the higher quality scan settings (10たm y-resolution) and which were deemed 
sufficiently noise free were used for these measurements, resulting in a reduction in overall 
group size. Qualitative observation of the angiographic SPD images shown in Fig. 8 shows 
the morphology of scans in the healthy, unaffected AD and mild AD cohorts are difficult to 
differentiate, as they all display long, thin vascular morphology. Comparatively scans of sites 
with severe localized AD showed a dense network of small, comparatively wide vessels. 
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Fig. 8. A selection of 2D angiographic OCT images projected over a depth range of ± 30たm 
around the detected SPD depth, showing morphological differences in the SPD. A-D) Scans 
from each data set captured from the cubital fossa (Elbow) skin site. E-H) Scans from each 
data set captured from the popliteal fossa (Knee) skin site. All images are 4x4mm. 
Through the quantitative measurements shown in Fig. 9, the measured mean vessel 
diameter was found to be significantly higher for patients with severe localized AD, when 
compared to all other data sets at both skin sites. The sole exception being the unaffected 
elbow, which did not quite reach significance (p = 0.058). Vascular enlargement is one of the 
primary alterations to the cutaneous circulation within inflammatory skin conditions such as 
AD, psoriasis and rosacea [43], thus it is unsurprising that the vessel diameter is measurable 
larger for severe cases of localized AD. 
Mean vessel segment length was significantly higher in the healthy data set than in the 
severe AD data set at both skin sites. This suggests that for severe localized AD patients, the 
individual vessel segments are shortened, with more branch points. There was however no 
significant discrimination in vessel segment length between healthy skin and skin graded as 
unaffected or mildly inflamed. Vessel density was found to be significantly higher for the 
severe AD data set when compared to all other data sets, with the unaffected elbow being the 
exception (p = 0.108). In general, these two metrics correspond to an observed increase in 
vessel growth and branching within the severe AD data set. This is expected, as lesioned skin 
affected by AD has previously been shown to exhibit higher levels of the angiogenic growth 
factor VEGF compared to healthy skin [44,45], which is associated with increased levels of 
vascular remodeling [46]. 
Lastly, the differences in fractal dimension between the healthy and severe data sets did 
not reach significance at the elbow site (p = 0.098), however a significant increase in fractal 
dimension was found for higher severities at the knee site suggesting those vessel networks 
became more tortuous and irregular as severity increased. Previously, the study of the fractal 
dimension of vascular networks has proven to be a fast, reliable and robust parameter for 
observing and evaluating angiographic processes [47], thus it may prove a useful metric when 
considering the increased angiogenic proliferation within AD. 
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Fig. 9. Bar charts showing the variance of quantitative parameters which were automatically 
extracted from the superficial vascular plexus layer of data sets following the binarization and 
skeletonization steps outlined in section 2.3. Columns: Mean depth. Bars: Standard deviation. 
Significance was calculated at each skin site independently using a one-way ANOVA followed 
by the Tukey-Kramer honest significance difference (HSD) test. H = Healthy, U = Unaffected, 
M = Mild localized AD, S = Severe localized AD. Numbers at the base of each column 
correspond to group size (n). 
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4. Conclusions 
Unequivocal assessment of the severity of AD is a challenging and subjective task to perform, 
particularly within flare-free AD patients. This is a result of many of the external, clinical 
features of the condition being characteristic, but not specific indicators of severity. Sub-
clinical measurements of epidermal thickening remain robust for areas exhibiting mild 
symptoms, but become increasingly difficult as the epidermis increasingly thickens due to the 
extension of the dermal papillae during acanthosis. Here we demonstrate how the 
visualization and quantification of the microcirculatory depth using OCT can be utilized as an 
alternative means of achieving this measurement, as the superficial plexus remains relatively 
flat regardless of its depth within the tissue. It is shown that the superficial plexus depth 
(SPD) differs significantly between healthy patients and those who are unaffected or suffering 
from mild or severe localized AD, and thus can potentially be utilized as a metric for 
monitoring the severity of the condition. Recent treatment strategies for AD emphasize the 
importance of treating a flare (e.g. with topical corticosteroids) beyond the point at which 
visible lesions have disappeared. Of particular relevance to this idea, we have shown that the 
SPD metric differs significantly (p = 0.04 at the elbow, p = 2.0 × 10−5 at the knee) between 
healthy (do not suffer from AD) subjects and AD subjects whose flares have indeed 
disappeared visually. Hence SPD depth has potential as a non-invasive biomarker of sub-
clinical inflammation. Furthermore, the morphology of the vessels themselves appear to be 
altered with the presence of AD, with significant changes in vessel diameter, length, density 
and fractal dimension between healthy and severe localized AD patients. These metrics 
provide a means of quantifying and differentiating between subtle changes in the condition, 
particularly past the point of clinical-remission. 
Limitations of the current study include the need to make physical contact with the skin 
surface, which may induce some degree of vasoconstriction within the observed vessels. 
Contactless scans were deemed impractical at the imaging speeds used herein, but faster OCT 
systems could potentially be used to acquire contactless angiographic scans without inducing 
excessive motion artefacts in the data. Furthermore, we only considered one algorithm for 
measuring the structural epidermal thickness. It is possible that more advanced detection 
algorithms will have a greater success rate for DEJ detection and should be considered 
moving forward. 
Future developments will focus on the further refinement of both angiographic and 
structural detection methods. In particular, the application of the techniques described herein 
to long-term clinical observations of drug and treatment efficacy may help to assess clinical 
benefit. Angiographic OCT may also provide a valuable guide to determining how long 
treatments for AD should be continued after visible lesions have resolved, in order to induce 
clearance of all sub-clinical manifestations of AD. This OCT biomarker can therefore be used 
to stratify patients into those requiring different durations of therapy to achieve optimal long-
term control of their AD. Angiographic OCT could also be used to determine the long-term 
safety of therapies such as topical corticosteroids, by providing a robust, non-invasive 
measure of epidermal atrophy. 
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